AKT1 and lip and oral cavity carcinoma: Several studies have reported that celecoxib inhibits adhesion and invasion in oral cancer, gastric cancer, colon cancer, lung cancer and osteosarcoma cells through various cell signaling pathways such as NF-kB, MMP-2/9, E-cadherin, β-catenin and AKT [59, 60].